NEWS..Deciphera Pharmaceuticals stock nearly doubles TUESDAY after the biotech said its stomach cancer treatment benefited patients who've
exhausted other options. The company is studying a drug called ripretinib in patients with gastrointestinal stromal tumors. This drug has not been approved yet, but investment and industry interest is MOVING HIGHER .
This company's management knows HOW TO GENERATE INTEREST IN THEIR DRUG CANDIDATE, PVCT 'S PRH GROUP DOES NOT...Dom prefers to have shareholders suffer from Horrific , UNJUSTIFIED SP .......WHY? Is he afraid he can't produce results ????
or is he inexperienced, clueless ... amateur
AFTER YEARS IN CONTROL, DIPLOMA DOM CAN ONLY PLACE BLAME AND HAS NOT INCREASED SHAREHOLDER EQUITY while readers enjoy the hopes generated by scientific speculation on this board by a few raising hopes with no confirmation by the markets. Makes for interesting read along with new UFO sightings "NANU NANU"